Fundraising Fox
/Companies
Sign in

Scala Bio

Founded 2022 · 34 employees on LinkedIn · 4 known investors

Find your way into Scala Bio

Each arrow is one introduction. Sign up to fill in the first one.

304 people can intro you to Sarel

Ask Reut Shema to introduce you to Sarel Fleishman

You →Reut · together at Weizmann Institute of Science →Sarel

112 people can intro you to Ravit

Ask Jamie Chen to introduce you to Ravit Netzer

You →Jamie · together at Scala Bio →Ravit

Sign up to find every way you can get introduced to Scala Bio

  • Your email: who you already know at Scala Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Scala Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Scala develops computational protein stability design technology that enables bacterial production of complex human enzymes, applied here to redesign human acetylcholinesterase (AChE) for high-yield, active expression in E. coli. The company's approach supports structural biology, enzyme engineering, and therapeutic and biodefense development in the biotechnology sector.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Scala Bio was founded in 2022 by Ravit Netzer and Adi Goldenzweig.

RNRavit Netzer
Ravit NetzerCo-founder & CEORavit Netzer holds a Ph.D. in computational protein design from the Weizmann Institute of Science and brings over a decade of experience in protein engineering, including developing antibody design tools and methods for enhancing protein specificity and affinity. She is co-founder and CEO of Scala Bio, which develops computational protein stability design technology for bacterial production of complex enzymes.
AGAdi Goldenzweig
Adi GoldenzweigCo-founder & CTO
SFSarel Fleishman
Sarel FleishmanChief ScientistSarel Fleishman is a professor at the Weizmann Institute of Science specializing in applied protein design, with expertise in antibody and enzyme engineering and methods for optimizing stability, expression, and activity in biologics.

Investors · 4

TLV Partnerslisted by TLV PartnersTel Aviv · $3M – $70M

How we know: TLV Partners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Deep InsightreportedTel Aviv

How we know: open dataset · investor-profiles · Not right? Tell us

Grove VenturesreportedTel Aviv-Yafo · $3.5M – $74M

How we know: a partner's Signal profile · Not right? Tell us

Frequently asked questions

What does Scala Bio do?
Scala develops computational protein stability design technology that enables bacterial production of complex human enzymes, applied here to redesign human acetylcholinesterase (AChE) for high-yield, active expression in E. coli. The company's approach supports structural biology, enzyme engineering, and therapeutic and biodefense development in the biotechnology sector.
Who founded Scala Bio?
Scala Bio was founded by Ravit Netzer, Adi Goldenzweig in 2022.
Who are Scala Bio's investors?
Scala Bio's investors include IT-Farm Corporation, TLV Partners, Deep Insight, Grove Ventures.